Brepocitinib yields improvements in cutaneous sarcoidosis

Medical Xpress - latest medical and health news stories ·
Health & Medicine United Kingdom

For patients with cutaneous sarcoidosis (CS), brepocitinib is associated with dose-dependent and clinically meaningful improvements, according to a study published online in JAMA Dermatology to coincide with the annual meeting of the American College of Rheumatology, held from Nov. 6 to 11 in Orlando, Florida.

Read original article on Medical Xpress - latest medical and health news stories →